Federal Register / Vol. 76, No. 31 / Tuesday, February 15, 2011 / Notices 8777 

The company plans to import small 

quantities of the listed controlled 

substances for the manufacture of 

analytical reference standards. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 952(a) 

and determined that the registration of 

Cerilliant Corporation to import the 

basic classes of controlled substances is 

consistent with the public interest and 

with United States obligations under 

international treaties, conventions, or 

protocols in effect on May 1, 1971. DEA 

has investigated Cerilliant Corporation 

to ensure that the company’s 

registration is consistent with the public 

interest. The investigation has included 

inspection and testing of the company’s 

physical security systems, verification 

of the company’s compliance with state 

and local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic classes of controlled 

substances listed. 

Dated: February 4, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–3407 Filed 2–14–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated October 8, 2010, and 

published in the Federal Register on 

October 20, 2010, (75 FR 64745), 

National Center for Natural Products 

Research-NIDA MProject, University of 

Mississippi, 135 Coy Waller Lab 

Complex, University, Mississippi 38677, 

made application by renewal to the 

Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of the following basic 

classes of controlled substances: 

Drug Schedule 

Marihuana (7360) ......................... I 

Tetrahydrocannabinols (7370) ..... I 

The company plans to cultivate 

marihuana for the National Institute on 

Drug Abuse for research approved by 

the Department of Health and Human 

Services. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

National Center for Natural Products 

Research-NIDA MProject to manufacture 

the listed basic classes of controlled 

substances is consistent with the public 

interest at this time. DEA has 

investigated National Center for Natural 

Products Research-NIDA MProject to 

ensure that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823(a), 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: February 4, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–3410 Filed 2–14–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated October 8, 2010 and 

published in the Federal Register on 

October 20, 2010, 75 FR 64744, GE 

Healthcare, 3350 North Ridge Avenue, 

Arlington Heights, Illinois 60004–1412, 

made application by renewal to the 

Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of Cocaine (9041), a basic 

class of controlled substance. 

The company plans to manufacture a 

radioactive product used in diagnostic 

imaging in the diagnosis of Parkinson’s 

Disease and for manufacture in bulk for 

investigational new drug (IND) 

submission and clinical trials. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of GE 

Healthcare to manufacture the listed 

basic class of controlled substance is 

consistent with the public interest at 

this time. DEA has investigated GE 

Healthcare to ensure that the company’s 

registration is consistent with the public 

interest. The investigation has included 

inspection and testing of the company’s 

physical security systems, verification 

of the company’s compliance with State 

and local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823(a), 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic class of controlled substance 

listed. 

Dated: February 4, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–3405 Filed 2–14–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated October 19, 2010, and 

published in the Federal Register on 

October 26, 2010, 75 FR 65659, 

Cedarburg Pharmaceuticals, Inc., 870 

Badger Circle, Grafton, Wisconsin 

53024, made application by renewal to 

the Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of the following basic 

classes of controlled substances: 

Drug Schedule 

Tetrahydrocannabinols (7370) ..... I 

Dihydromorphine (9145) ............... I 

Dihydrocodeine (9120) ................. II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Hydrocodone (9193) ..................... II 

Remifentanil (9739) ...................... II 

Sufentanil (9740) .......................... II 

Fentanyl (9801) ............................ II 

The company plans to manufacture 

the listed controlled substances in bulk 

for distribution to its customers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Cedarburg Pharmaceuticals, Inc. to 

manufacture the listed basic classes of 

controlled substances is consistent with 

the public interest at this time. DEA has 

investigated Cedarburg Pharmaceuticals, 

Inc. to ensure that the company’s 

registration is consistent with the public 

interest. The investigation has included 

inspection and testing of the company’s 

physical security systems, verification 

of the company’s compliance with state 

and local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823(a), 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 


jdjones on DSK8KYBLC1PROD with NOTICES